Evicel Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high intraoperative bleeding risks, limitations of mechanical hemostasis, adoption of plasma-derived products, increasing complex surgeries, focus on patient safety.

The growth in the forecast period can be attributed to growth in minimally invasive surgeries, rising surgical volumes, expanding specialty clinics, innovation in surgical biomaterials, increased focus on surgical efficiency. Major trends in the forecast period include increasing use of fibrin sealants in surgery, rising demand for biocompatible hemostatic agents, growth in cardiovascular and liver surgeries, preference for human plasma derived sealants, expansion of advanced surgical procedures.

The increasing prevalence of bleeding disorders is expected to drive the growth of the evicel market. Bleeding disorders are conditions in which the blood cannot clot properly, resulting in excessive or prolonged bleeding after injury or surgery. The rise in these disorders is attributed to factors such as genetic conditions like hemophilia, lifestyle factors including poor nutrition and obesity, and the growing prevalence of chronic diseases such as liver disorders that impair clotting. Evicel is used as a fibrin sealant to promote hemostasis during surgical procedures, particularly in patients with coagulation challenges, including those with hemophilia or other clotting deficiencies. For example, in May 2025, Pfizer Inc., a US-based biopharmaceutical company, reported that in the UK, the hemophilia A and B patient population exceeded 11,800 individuals in the 2023/2024 period. Therefore, the rising prevalence of bleeding disorders is driving the growth of the evicel market.

The growing demand for aesthetic surgeries is also expected to propel the growth of the evicel market. Aesthetic surgeries include non-invasive or minimally invasive procedures designed to enhance physical appearance, improve skin texture, and reduce signs of aging, such as wrinkles, fine lines, and sagging skin. The increasing demand for these procedures is fueled by factors such as higher incomes, aging populations, social media influence, and advancements in cosmetic technologies. Evicel is applied in aesthetic surgeries to improve wound closure and minimize post-operative complications, helping reduce scarring and promote better healing, which aligns with the precision required in cosmetic procedures. For example, in June 2024, the International Society of Aesthetic Plastic Surgery, a US-based professional organization, reported that total surgical and non-surgical procedures rose by 3.4% in 2023, reaching 34.9 million, with face and head procedures exceeding 6.5 million, a 19.6% year-over-year increase. Therefore, the rise in demand for aesthetic surgeries is supporting the growth of the evicel market.

The rising prevalence of chronic conditions is also expected to boost the growth of the evicel market. Chronic conditions are long-term illnesses, lasting a year or more, that require ongoing care or restrict daily activities, such as diabetes and heart disease. The increase in chronic conditions is driven by aging populations, unhealthy lifestyles, environmental factors, and improved diagnostic capabilities. Evicel is commonly used as a fibrin sealant to control bleeding during surgeries, especially in patients with chronic diseases that may impair wound healing or clotting. Its use helps achieve hemostasis and reduces complications during surgical procedures in these patients. For example, in March 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes it increased by 21%, and the percentage achieving target HbA1c levels rose to 37.9%, the highest ever recorded. Therefore, the rising prevalence of chronic conditions is driving the growth of the evicel market.

Major companies operating in the evicel market are Johnson & Johnson (Omrix Biopharmaceuticals Ltd)

North America was the largest region in the evicel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the evicel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the evicel market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the evicel market by increasing the cost of sourcing human plasma components, biologic processing equipment, and cold chain logistics. These effects are most evident in hospital pharmacy distribution channels and regions dependent on cross border biologic supply chains such as europe and asia pacific. Elevated costs can influence procurement and surgical material budgets. However, tariffs are also supporting localized plasma processing and strengthening regional supply security for surgical sealants.

The evicel market research report is one of a series of new reports that provides evicel market statistics, including evicel industry global market size, regional shares, competitors with a evicel market share, detailed evicel market segments, market trends and opportunities, and any further data you may need to thrive in the evicel industry. This evicel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Evicel is a surgical fibrin sealant composed of human fibrinogen and thrombin, used to control bleeding and support healing by forming a clot during procedures. It is commonly applied in surgeries that require precise bleeding management, including cardiovascular, liver, and orthopedic operations. Its biocompatibility minimizes the risk of adverse reactions, ensuring patient safety.

The main types of surgeries for evicel include orthopedic, cardiac, general, liver, and gynecological procedures. Orthopedic surgeries involve treating musculoskeletal conditions, such as fractures, joint replacements, and spinal disorders. These procedures often require hemostatic agents like Evicel to manage bleeding, especially in complex operations such as hip replacements or spinal surgeries. Distribution channels primarily include hospital pharmacies, surgical supply distributors, and outpatient surgery centers, with use in hospitals, specialty clinics, and other healthcare settings.

The evicel market consists of sales of fibrin sealant kits, hemostatic applicators, wound closure aids, and spray applicators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.